Search Result

Results for "

major depressive disorder

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (11) Dopamine Transporter (1) HDAC (1) iGluR (2) Isotope-Labeled Compounds (4) Monoamine Oxidase (3) Monoamine Transporter (1) mTOR (1) Opioid Receptor (3) Serotonin Transporter (17) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (7) Neurological Disease (33)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0478A

Trazodone 2 Publications Verification AF-1161 free base	5-HT Receptor	Neurological Disease
Trazodone (AF-1161 free base) is a serotonin receptor antagonist and reuptake inhibitor. Trazodone can be used for the research of major depressive disorder. Trazodone also has potential for sleep disorder research .

HY-14262

Vilazodone 4 Publications Verification EMD 68843; SB659746A	5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-B0161A

Duloxetine hydrochloride 4 Publications Verification (S)-Duloxetine hydrochloride; LY-248686 hydrochloride	Serotonin Transporter	Neurological Disease Cancer
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-154977

ETAP	Monoamine Oxidase	Neurological Disease Cancer
ETAP is a MAO-A and MAO-B inhibitor. ETAP has antidepressant-like effect. ETAP can be used for research of major depressive disorder .

HY-160207

ABX-002 MA-JD21	Thyroid Hormone Receptor	Neurological Disease
ABX-002 (MA-JD21 )is a TR-β selective CNS-penetrant TR-β agonist prodrug and can be used for study of major depressive disorder (MDD) .

HY-B0478AR

Trazodone (Standard)	5-HT Receptor	Neurological Disease
Trazodone (Standard) is the analytical standard of Trazodone. This product is intended for research and analytical applications. Trazodone (AF-1161 free base) is a serotonin receptor antagonist and reuptake inhibitor. Trazodone can be used for the research of major depressive disorder. Trazodone also has potential for sleep disorder research .

HY-14262R

Vilazodone (Standard)	5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (Standard) is the analytical standard of Vilazodone. This product is intended for research and analytical applications. Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-14262S1

Vilazodone-d8 hydrochloride EMD 68843-d8; SB659746A-d8	5-HT Receptor Serotonin Transporter Isotope-Labeled Compounds	Neurological Disease
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-B0161

Duloxetine LY248686	Serotonin Transporter	Neurological Disease Cancer
Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0176A

Sertraline hydrochloride Maximum Cited Publications 9 Publications Verification	Serotonin Transporter	Neurological Disease Cancer
Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-16728B

Rapastinel Trifluoroacetate 1 Publications Verification GLYX-13 Trifluoroacetate	iGluR	Neurological Disease
Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.

HY-B0161AS

Duloxetine D3 hydrochloride (S)-Duloxetine-d₃ (hydrochloride); LY248686-d₃ (hydrochloride)	Serotonin Transporter	Neurological Disease
Duloxetine-d₃ (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].

HY-B0161E

(±)-Duloxetine hydrochloride (Rac)-Duloxetine hydrochloride	Serotonin Transporter	Neurological Disease
(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .

HY-B0478

Trazodone hydrochloride 2 Publications Verification AF-1161	5-HT Receptor	Neurological Disease
Trazodone hydrochloride (AF-1161) is a serotonin receptor antagonist and reuptake inhibitor with anti-neuroinflammatory effects. Trazodone hydrochloride can be used for research in major depressive disorder and also holds potential for studies related to sleep disorders .

HY-19686

Ipsapirone TVX Q 7821 free base	5-HT Receptor	Neurological Disease
Ipsapirone (TVX Q 7821) is an anxiolytic compound and a 5-HT_1A receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits 5-HT_1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT₂ and the α₁-adrenergic function .

HY-19686A

Ipsapirone hydrochloride TVX Q 7821	5-HT Receptor	Neurological Disease
Ipsapirone hydrochloride (TVX Q 7821) is an anxiolytic compound and a 5-HT_1A receptor partial agonist. Ipsapirone hydrochloride (TVX Q 7821) also exhibits 5-HT_1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT₂ and the α₁-adrenergic function .

HY-B0161S

Duloxetine-d7	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
Duloxetine-d₇ ((S)-Duloxetine-d₇) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].

HY-B0161AR

Duloxetine hydrochloride (Standard) (S)-Duloxetine hydrochloride (Standard); LY-248686 hydrochloride (Standard)	Serotonin Transporter	Neurological Disease Cancer
Duloxetine (hydrochloride) (Standard) is the analytical standard of Duloxetine (hydrochloride). This product is intended for research and analytical applications. Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-19907

Liafensine BMS-820836	Monoamine Transporter Dopamine Transporter Serotonin Transporter	Neurological Disease
Liafensine (BMS-820836) is a triple monoamine reuptake inhibitor (TRI), that inhibits dopamine transporter, serotonin transporter and norepinephrine transporter, with IC₅₀s of 5.67, 1.08 and 7.99 nM, respectively. Liafensine exhibits antidepressant activity .

HY-118615

LY2048978	Opioid Receptor	Neurological Disease
LY2048978 is a non-selective opioid receptor antagonist with K_i of 0.287, 0.471 and 1.05 nM for human mu, kappa and delta opioid receptors in vitro, respectively. LY2048978 can be used in the research of major depressive disorder and alcohol use disorder .

HY-B0176AS1

(±)-cis-Sertraline-d3 hydrochloride	Serotonin Transporter	Neurological Disease
(±)-cis-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive[1][2].

HY-B0176AS

rel-Sertraline-d3 hydrochloride	Serotonin Transporter	Neurological Disease
rel-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive[1][2].

HY-B0176AR

Sertraline hydrochloride (Standard)	Serotonin Transporter	Neurological Disease Cancer
Sertraline (hydrochloride) (Standard) is the analytical standard of Sertraline (hydrochloride). This product is intended for research and analytical applications. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-B0161AS1

Duloxetine-d7 hydrochloride (S)-Duloxetine-d₇ hydrochloride; LY248686-d₇ hydrochloride	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease Cancer
Duloxetine-d7 hydrochloride ((S)-Duloxetine-d7 hydrochloride) is the deuterium labeled Duloxetine hydrochloride (HY-B0161A). Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0161ES

(±)-Duloxetine-d3 hydrochloride (Rac)-Duloxetine-d₃ hydrochloride	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
(±)-Duloxetine-d₃ (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research[1].

HY-168508

PB200	HDAC	Neurological Disease
PB200 is an HDAC6 inhibitor with an IC₅₀ value of 1.97 nM. PB200 demonstrates significant antidepressant effects by restoring abnormal HDAC6 expression levels and alleviating neuroinflammation .

HY-122422

Gepirone	5-HT Receptor	Others
Gepirone is a selective and affinitive 5-HT_1A agonist. Gepirone binds selectively to 5-HT_1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research .

HY-109046

Tulrampator 1 Publications Verification CX-1632; S-47445	iGluR mTOR	Neurological Disease
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .

HY-14198

Selegiline Deprenyl; (-)-Selegiline; (-)-Deprenyl	Monoamine Oxidase	Neurological Disease
Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-14199

Selegiline hydrochloride 5+ Cited Publications Deprenyl hydrochloride; (-)-Selegiline hydrochloride; (-)-Deprenyl hydrochloride	Monoamine Oxidase	Neurological Disease
Selegiline (Deprenyl) hydrochloride is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline hydrochloride exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline hydrochloride can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-114452

LY2940094 1 Publications Verification BTRX-246040	Opioid Receptor	Neurological Disease
LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .

HY-114452A

LY2940094 tartrate BTRX-246040 tartrate	Opioid Receptor	Neurological Disease
LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models .

HY-122422R

Gepirone (Standard)	5-HT Receptor	Others
Gepirone (Standard) is the analytical standard of Gepirone. This product is intended for research and analytical applications. Gepirone is a selective and affinitive 5-HT_1A agonist. Gepirone binds selectively to 5-HT_1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research .

HY-W052508

Norquetiapine N-Desalkylquetiapine	5-HT Receptor	Neurological Disease
Norquetiapine is an antidepressant and neuroprotective agent and is the active metabolic component of Quetiapine (HY-14544). Norquetiapine is also a partial 5-HT1A receptor agonist, and a presynaptic α2, 5-HT2C and 5-HT7 b> Receptor antagonist. Norquetiapine can also selectively inhibit norepinephrine transporter (NET), inhibit norepinephrine reuptake, and has potential inhibitory effects on bipolar depression, major depressive disorder, and generalized anxiety disorder. Norquetiapine demonstrated in vivo activity in forced swimming in mice and learned helplessness tests in rats .

Cat. No.	Product Name

HY-L108

Antidepressant Compound Library	1,826 compounds
Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors. Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent. MCE offers a unique collection of 1,826 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Antidepressant Compound Library

1,826 compounds

Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors.

Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent.

MCE offers a unique collection of 1,826 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Cat. No.	Product Name	Chemical Structure